^
Association details:
| Biomarker: | CD38 expression |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | ISB 1342 (CD3 agonist, CD38 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ISB 1342: A first-in-class CD38 T cell engager for the treatment of relapsed refractory multiple myeloma.
Published date:
05/19/2021
Excerpt:
In vitro, ISB 1342 killed a large range of CD38-expressing tumor cell lines (EC50:12 to 90 pM) with 8 to 239-fold superior efficacy than daratumumab…the potency of ISB 1342 was assessed in vivo in a therapeutic model of a subcutaneously established Daudi tumor co-xenografted with human PBMCs. In marked contrast to daratumumab, which induced only a partial tumor control, ISB 1342 induced complete tumor eradication when injected intravenously weekly at 0.5 mg/kg.
DOI:
10.1200/JCO.2021.39.15_suppl.8044
